Citadel Advisors’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.13M | Buy |
1,225,310
+148,949
| +14% | +$180K | ﹤0.01% | 7407 |
|
|
2025
Q4 | $1.38M | Buy |
1,076,361
+587,918
| +120% | +$790K | ﹤0.01% | 6706 |
|
|
2025
Q3 | $635K | Buy |
488,443
+139,283
| +40% | +$182K | ﹤0.01% | 8556 |
|
|
2025
Q2 | $419K | Buy |
+349,160
| New | +$387K | ﹤0.01% | 9043 |
|
|
2025
Q1 | – | Sell |
-81,589
| Closed | -$115K | – | 15095 |
|
|
2024
Q4 | $143K | Buy |
81,589
+15,919
| +24% | +$29.7K | ﹤0.01% | 10963 |
|
|
2024
Q3 | $127K | Sell |
65,670
-839,676
| -93% | -$1.64M | ﹤0.01% | 10799 |
|
|
2024
Q2 | $1.6M | Buy |
+905,346
| New | +$2.21M | ﹤0.01% | 5727 |
|
|
2024
Q1 | – | Sell |
-71,319
| Closed | -$172K | – | 15073 |
|
|
2023
Q4 | $158K | Sell |
71,319
-42,206
| -37% | -$90.1K | ﹤0.01% | 10307 |
|
|
2023
Q3 | $329K | Buy |
113,525
+33,495
| +42% | +$87.6K | ﹤0.01% | 8986 |
|
|
2023
Q2 | $154K | Sell |
80,030
-33,488
| -30% | -$66.1K | ﹤0.01% | 10298 |
|
|
2023
Q1 | $221K | Buy |
113,518
+91,512
| +416% | +$181K | ﹤0.01% | 10004 |
|
|
2022
Q4 | $25.7K | Buy |
22,006
+9,973
| +83% | +$12.3K | ﹤0.01% | 12915 |
|
|
2022
Q3 | $13K | Sell |
12,033
-251,248
| -95% | -$380K | ﹤0.01% | 12201 |
|
|
2022
Q2 | $421K | Buy |
263,281
+208,289
| +379% | +$515K | ﹤0.01% | 9048 |
|
|
2022
Q1 | $197K | Sell |
54,992
-49,655
| -47% | -$172K | ﹤0.01% | 11561 |
|
|
2021
Q4 | $410K | Buy |
104,647
+42,494
| +68% | +$199K | ﹤0.01% | 10153 |
|
|
2021
Q3 | $410K | Sell |
62,153
-34,379
| -36% | -$226K | ﹤0.01% | 10352 |
|
|
2021
Q2 | $595K | Sell |
96,532
-20,001
| -17% | -$107K | ﹤0.01% | 9644 |
|
|
2021
Q1 | $527K | Buy |
116,533
+56,162
| +93% | +$308K | ﹤0.01% | 9565 |
|
|
2020
Q4 | $362K | Sell |
60,371
-172,535
| -74% | -$1.13M | ﹤0.01% | 8750 |
|
|
2020
Q3 | $1.73M | Buy |
+232,906
| New | +$1.61M | ﹤0.01% | 5004 |
|
|
2020
Q2 | – | Sell |
-45,063
| Closed | -$157K | – | 10193 |
|
|
2020
Q1 | $114K | Buy |
+45,063
| New | +$148K | ﹤0.01% | 8541 |
|
|
2019
Q4 | – | Sell |
-491,015
| Closed | -$2.27M | – | 9452 |
|
|
2019
Q3 | $2.27M | Sell |
491,015
-478,225
| -49% | -$3.77M | ﹤0.01% | 4274 |
|
|
2019
Q2 | $11.9M | Buy |
969,240
+53,125
| +6% | +$677K | 0.01% | 1967 |
|
|
2019
Q1 | $12.2M | Buy |
916,115
+865,653
| +1,715% | +$9.12M | 0.01% | 1837 |
|
|
2018
Q4 | $435K | Buy |
50,462
+17,721
| +54% | +$138K | ﹤0.01% | 6618 |
|
|
2018
Q3 | $245K | Buy |
32,741
+16,356
| +100% | +$116K | ﹤0.01% | 7906 |
|
|
2018
Q2 | $98K | Buy |
+16,385
| New | +$93.4K | ﹤0.01% | 8251 |
|
|
2018
Q1 | – | Sell |
-12,244
| Closed | -$80.4K | – | 8546 |
|
|
2017
Q4 | $72K | Buy |
+12,244
| New | +$67K | ﹤0.01% | 7527 |
|
|
2017
Q2 | – | Sell |
-150,332
| Closed | -$855K | – | 7806 |
|
|
2017
Q1 | $855K | Buy |
150,332
+7,844
| +6% | +$49.7K | ﹤0.01% | 4228 |
|
|
2016
Q4 | $1.04M | Buy |
142,488
+112,847
| +381% | +$709K | ﹤0.01% | 3805 |
|
|
2016
Q3 | $237K | Buy |
+29,641
| New | +$272K | ﹤0.01% | 6059 |
|
|
2016
Q2 | – | Sell |
-12,729
| Closed | -$120K | – | 7118 |
|
|
2016
Q1 | $103K | Sell |
12,729
-258,262
| -95% | -$1.86M | ﹤0.01% | 6013 |
|
|
2015
Q4 | $2.93M | Sell |
270,991
-355,930
| -57% | -$3.5M | ﹤0.01% | 2353 |
|
|
2015
Q3 | $5.08M | Buy |
626,921
+563,707
| +892% | +$8.87M | ﹤0.01% | 1935 |
|
|
2015
Q2 | $1.53M | Buy |
+63,214
| New | +$2M | ﹤0.01% | 3381 |
|
|
2015
Q1 | – | Sell |
-3,317
| Closed | -$131K | – | 8697 |
|
|
2014
Q4 | $112K | Buy |
+3,317
| New | +$93.9K | ﹤0.01% | 6551 |
|
|
2014
Q3 | – | Sell |
-9,639
| Closed | -$271K | – | 8271 |
|
|
2014
Q2 | $283K | Sell |
9,639
-20,620
| -68% | -$661K | ﹤0.01% | 5132 |
|
|
2014
Q1 | $1.33M | Buy |
30,259
+6,478
| +27% | +$285K | ﹤0.01% | 3069 |
|
|
2013
Q4 | $911K | Buy |
+23,781
| New | +$700K | ﹤0.01% | 3308 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
Citadel Advisors's LAB Position: Q1 2026 in Review
Citadel Advisors increased its Standard BioTools (LAB) stake by 14% in Q1 2026, buying an estimated $180K and bringing the position to 1,225,310 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #7407.
Citadel Advisors first reported a position in LAB in Q4 2013 and has held it in 40 quarters since. The position peaked at $12.2M in Q1 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- Citadel Advisors held 1,225,310 shares of Standard BioTools worth $1.13M as of Q1 2026.
- Citadel Advisors bought 148,949 Standard BioTools shares in Q1 2026, an estimated $180K.
- Standard BioTools made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7407 holding.
- Citadel Advisors first reported a position in Standard BioTools in Q4 2013 and has held it in 40 quarters since.
- Citadel Advisors's Standard BioTools position peaked at $12.2M in Q1 2019.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.